Biogen Inc.

As of June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh carries a market capitalization of 46.55T, placing it among publicly traded companies globally. Its enterprise value stands at 57.04T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh has 1.79B shares outstanding.

As of June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh trades at a trailing price-to-earnings ratio of 37.43. The price-to-sales ratio is 3.12, and the price-to-book ratio stands at 1.66.

As of June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh trades at an EV/EBITDA multiple of 19.85 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 35.14 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh trades at an EV/FCF ratio of 14.11, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 57.04T versus a market cap of 46.55T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 44.33, indicating elevated leverage, while an interest coverage ratio of 6.80 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh posted a return on equity (ROE) of 4.58, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.50 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.76, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.16, useful for judging operating efficiency across full business cycles. The company generates approximately 1.98B in revenue per employee across its workforce of 7,526.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.12 indicates how many times Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh recorded 262.28B in income tax expense. That works out to an effective tax rate of 17.48, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.50T, leaving 1.24T in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh's stock has gained approximately 74.73% over the past 52 weeks. The 50-day moving average sits at 26,588.60, while the 200-day moving average is 21,955.80.

Over the twelve months ended June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh generated 14.88T in revenue and converted that into 1.24T in net income, yielding earnings per share of 689.81. EBITDA reached 2.87T, while operating income came in at 2.87T.

As of June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh holds 1.91T in cash and equivalents against 12.39T in total debt, resulting in a net debt position of 10.10T. Total book value stands at 27.96T, with working capital of 5.03T providing operational flexibility.

Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh produced 4.27T in operating cash flow over the twelve months ended June 30, 2026. After subtracting -576.78B in capital expenditures, free cash flow totaled 3.69T - equivalent to 2,067.46 per share.

Over the twelve months ended June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh posted a gross margin of 73.99, reflecting its pricing power and cost economics. The operating margin of 19.29 and net profit margin of 8.32 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 7.93, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -3.14, meaning Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Biogen Inc Shs Cert Deposito Arg Repr 1/13 Sh has an Altman Z-Score of 5.73, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.